PortalPublikationenUrinary cytology and nuclear matrix protein 22 in the detect...

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.

Standard

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. / Hutterer, Georg C; Karakiewicz, Pierre I; Zippe, Craig; Lüdecke, Gerson; Boman, Hans; Sanchez-Carbayo, Marta; Casella, Roberto; Mian, Christine; Friedrich, Martin; Eissa, Sanaa; Akaza, Hideyuki; Serretta, Vincenzo; Hedelin, Hans; Rupesh, Raina; Miyanaga, Naoto; Sagalowsky, Arthur I; Perrotte, Paul; Lotan, Yair; Marberger, Michael J; Shariat, Shahrokh F.

in: BJU INT, Jahrgang 101, Nr. 5, 5, 2008, S. 561-565.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hutterer, GC, Karakiewicz, PI, Zippe, C, Lüdecke, G, Boman, H, Sanchez-Carbayo, M, Casella, R, Mian, C, Friedrich, M, Eissa, S, Akaza, H, Serretta, V, Hedelin, H, Rupesh, R, Miyanaga, N, Sagalowsky, AI, Perrotte, P, Lotan, Y, Marberger, MJ & Shariat, SF 2008, 'Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.', BJU INT, Jg. 101, Nr. 5, 5, S. 561-565. <http://www.ncbi.nlm.nih.gov/pubmed/18257856?dopt=Citation>

APA

Hutterer, G. C., Karakiewicz, P. I., Zippe, C., Lüdecke, G., Boman, H., Sanchez-Carbayo, M., Casella, R., Mian, C., Friedrich, M., Eissa, S., Akaza, H., Serretta, V., Hedelin, H., Rupesh, R., Miyanaga, N., Sagalowsky, A. I., Perrotte, P., Lotan, Y., Marberger, M. J., & Shariat, S. F. (2008). Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU INT, 101(5), 561-565. [5]. http://www.ncbi.nlm.nih.gov/pubmed/18257856?dopt=Citation

Vancouver

Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M et al. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU INT. 2008;101(5):561-565. 5.

Bibtex

@article{cd621f5abf1c46cf9227d34ba4362a74,
title = "Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.",
abstract = "OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test (>or=10 units/mL) and 80 (3.0%) had non-TCC recurrence. Most of these, i.e. 60 (75%), were stage >or=T2. The sensitivity and specificity of urinary cytology were, respectively, 20.0% and 94.8%, vs 77.5% and 81.8% for NMP22 of >or=10 units/mL. The predictive accuracy of urinary cytology was 57.5%, vs 87.1% for NMP22 >or= 10 units/mL. A combined model that included dichotomized NMP22 and urinary cytology was 85.3% accurate. CONCLUSION: The ability of a NMP22 level of >or=10 units/mL to predict non-TCC recurrence was better than that of urinary cytology, suggesting that NMP22 might have a role in the surveillance of patients at risk of non-TCC recurrence.",
author = "Hutterer, {Georg C} and Karakiewicz, {Pierre I} and Craig Zippe and Gerson L{\"u}decke and Hans Boman and Marta Sanchez-Carbayo and Roberto Casella and Christine Mian and Martin Friedrich and Sanaa Eissa and Hideyuki Akaza and Vincenzo Serretta and Hans Hedelin and Raina Rupesh and Naoto Miyanaga and Sagalowsky, {Arthur I} and Paul Perrotte and Yair Lotan and Marberger, {Michael J} and Shariat, {Shahrokh F}",
year = "2008",
language = "Deutsch",
volume = "101",
pages = "561--565",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.

AU - Hutterer, Georg C

AU - Karakiewicz, Pierre I

AU - Zippe, Craig

AU - Lüdecke, Gerson

AU - Boman, Hans

AU - Sanchez-Carbayo, Marta

AU - Casella, Roberto

AU - Mian, Christine

AU - Friedrich, Martin

AU - Eissa, Sanaa

AU - Akaza, Hideyuki

AU - Serretta, Vincenzo

AU - Hedelin, Hans

AU - Rupesh, Raina

AU - Miyanaga, Naoto

AU - Sagalowsky, Arthur I

AU - Perrotte, Paul

AU - Lotan, Yair

AU - Marberger, Michael J

AU - Shariat, Shahrokh F

PY - 2008

Y1 - 2008

N2 - OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test (>or=10 units/mL) and 80 (3.0%) had non-TCC recurrence. Most of these, i.e. 60 (75%), were stage >or=T2. The sensitivity and specificity of urinary cytology were, respectively, 20.0% and 94.8%, vs 77.5% and 81.8% for NMP22 of >or=10 units/mL. The predictive accuracy of urinary cytology was 57.5%, vs 87.1% for NMP22 >or= 10 units/mL. A combined model that included dichotomized NMP22 and urinary cytology was 85.3% accurate. CONCLUSION: The ability of a NMP22 level of >or=10 units/mL to predict non-TCC recurrence was better than that of urinary cytology, suggesting that NMP22 might have a role in the surveillance of patients at risk of non-TCC recurrence.

AB - OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test (>or=10 units/mL) and 80 (3.0%) had non-TCC recurrence. Most of these, i.e. 60 (75%), were stage >or=T2. The sensitivity and specificity of urinary cytology were, respectively, 20.0% and 94.8%, vs 77.5% and 81.8% for NMP22 of >or=10 units/mL. The predictive accuracy of urinary cytology was 57.5%, vs 87.1% for NMP22 >or= 10 units/mL. A combined model that included dichotomized NMP22 and urinary cytology was 85.3% accurate. CONCLUSION: The ability of a NMP22 level of >or=10 units/mL to predict non-TCC recurrence was better than that of urinary cytology, suggesting that NMP22 might have a role in the surveillance of patients at risk of non-TCC recurrence.

M3 - SCORING: Zeitschriftenaufsatz

VL - 101

SP - 561

EP - 565

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 5

M1 - 5

ER -